TATDN1 Activators
TATDN1 activators encompass a range of chemical compounds that exert their influence through various cellular mechanisms to enhance the functional activity of TATDN1. Forskolin, by elevating intracellular levels of cAMP, indirectly activates TATDN1 via PKA-dependent phosphorylation. This process serves to enhance TATDN1's role within its specific signaling pathways. Similarly, the tyrosine kinase inhibitor Genistein allows for increased TATDN1 activity by reducing competitive signaling, thereby freeing up pathways in which TATDN1 is a key player. Sphingosine-1-phosphate acts through its receptors to initiate signaling cascades that converge on the activation of TATDN1.
The broad-spectrum kinase inhibitor Staurosporine has the potential to selectively enhance TATDN1 activity by inhibiting kinases that negatively affect it. The calcium ionophore A23187 increases intracellular calcium, facilitating the activation of calcium-dependent signaling pathways that can enhance TATDN1. Finally, EGCG, by inhibiting specific kinases, may indirectly increase the activity of TATDN1, rounding out the list of compounds that serve to amplify TATDN1's functional role without directly altering its expression levels. Collectively, these chemicals orchestrate a symphony of biochemical events that culminate in the enhanced activity of TATDN1, each acting through distinct but complementary pathways.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin activates adenylate cyclase, thereby increasing cAMP levels in cells. Elevated cAMP activates PKA, which can phosphorylate TATDN1, leading to its enhanced functional activity. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $45.00 $164.00 $200.00 $402.00 $575.00 $981.00 $2031.00 | 46 | |
Genistein is a tyrosine kinase inhibitor. By inhibiting competitive tyrosine kinase signaling, it may indirectly upregulate signaling pathways that lead to TATDN1 activation. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $165.00 $322.00 $570.00 $907.00 $1727.00 | 7 | |
Sphingosine-1-phosphate binds to its G protein-coupled receptors, initiating a signaling cascade that can lead to the activation of TATDN1 through downstream effectors. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA activates protein kinase C (PKC), which is involved in various signaling pathways. PKC activation can lead to the phosphorylation and subsequent activation of TATDN1. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a broad-spectrum kinase inhibitor. By selectively inhibiting kinases that negatively regulate TATDN1, it may enhance TATDN1 activity indirectly. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
A23187 acts as a calcium ionophore, increasing intracellular calcium levels. This can activate calcium-dependent signaling pathways that enhance the functional activity of TATDN1. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG is a kinase inhibitor that may influence pathways by inhibiting kinases that otherwise modulate TATDN1 activity, leading to an indirect enhancement of TATDN1's function. | ||||||